Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Grafton

(Sharecast News) - Analysts at Berenberg hiked their target price on building materials company Grafton from 1,100.0p to 1,200.0p on Friday, citing an "attractive opportunity". Berenberg said while trading conditions remain "challenging" for Grafton, illustrated by expectation for a 15% decline in profit this year, it maintained its positive view for three reasons.

"Firstly, we expect more favourable market conditions from 2025 - in terms of both volumes and pricing - driving a recovery in profit. Secondly, we note an attractive capital returns story, with Grafton returning about 8% of its market cap per annum, on an ongoing basis, through a mix of buybacks and dividends. Finally, we see upside risk from the group deploying its surplus capital into value-enhancing acquisitions," said Berenberg.

The German bank, which reiterated its 'buy' rating on the stock, also noted that Grafton trades on 18x and 15x its 2024 and 2025 earnings per share forecasts.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Mkango and CoTec appoint lead engineers for DFW hub project
(Sharecast News) - Mkango Resources, alongside its partner CoTec Holdings, announced the appointment of PegasusTSI and BBA USA on Tuesday, to provide engineering, procurement and construction management (EPCM) services for the HyProMag USA rare earth magnet recycling and manufacturing project in the Dallas-Fort Worth area.
Videndum says debt discussions progressing positively
(Sharecast News) - Videndum said in an update on Tuesday that its debt discussions were progressing, as it confirmed it would publish its audited results for the year ended 31 December on 30 April.
Ricardo set to end year in line with expectations
(Sharecast News) - Ricardo said in an update on Tuesday that it expects to deliver financial performance for the 2024-2025 financial year within the range of analyst expectations, supported by a high level of secured and pipeline net revenue across all business units.
AstraZeneca receives positive Phase III trial results from Enhertu study
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its Enhertu candidate.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.